Mitochondrial protein import disorder

Mitochondrial protein import disorders are a group of rare genetic conditions in which the cellular machinery responsible for transporting proteins into mitochondria is impaired. Mitochondria rely on the import of the vast majority of their proteins from the cytoplasm, a process mediated by specialized translocase complexes (such as the TIM and TOM complexes) and associated chaperones. When components of this import machinery are defective, mitochondrial function is broadly compromised, leading to deficient oxidative phosphorylation and energy production. These disorders can affect multiple organ systems, particularly those with high energy demands, including the brain, skeletal muscle, heart, and liver. Clinical features are highly variable depending on the specific gene involved but commonly include developmental delay, intellectual disability, hypotonia, seizures, lactic acidosis, cardiomyopathy, and progressive neurodegeneration. Some subtypes present in the neonatal or infantile period with severe, life-threatening multisystem disease, while others may have a somewhat later onset. Specific subtypes within this group include disorders caused by mutations in genes such as TIMM50, TIMM8A (Mohr-Tranebjærg syndrome/deafness-dystonia-optic neuronopathy syndrome), PAM16, and others encoding components of the mitochondrial import pathway. There is currently no curative treatment for mitochondrial protein import disorders. Management is supportive and symptomatic, focusing on seizure control, nutritional support, cardiac monitoring, physical therapy, and management of metabolic crises. Mitochondrial cofactor supplementation (such as coenzyme Q10, riboflavin, and other vitamins) may be trialed, though evidence for efficacy is limited. Prognosis varies considerably depending on the specific genetic defect and severity of organ involvement.

Common questions about Mitochondrial protein import disorder